Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

Follow the links below to read about each product:

Camzyos (Bristol Myers Squibb)

Enhertu (Daiichi Sankyo, AstraZeneca)

Rebyota (Ferring Pharmaceuticals)

Sunlenca (Gilead Sciences)

Tzield (Provention Bio, a Sanofi company)

Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.

Articles in this issue

over 2 years ago

Article

Pharmaceutical Executive, September 2023 Issue (PDF)

over 2 years ago

Article

A New Era of Ethical Leadership

over 2 years ago

Article

Survival Story: Enhertu

over 2 years ago

Article

Gut Instinct: Rebyota

over 2 years ago

Article

Delaying Disease Onset: Tzield

over 2 years ago

Article

New Beginnings: Sunlenca

over 2 years ago

Article

A Heartfelt Solution: Camzyos

over 2 years ago

Article

Fortifying Defenses Pre-Patent Cliff

over 2 years ago

Article

New Product Planning: The Function's Evolution in Pharma

over 2 years ago

Article

No Rate Relief in Sight for Biotech

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!